AVP-923, formerly referred to by the proposed trade name Zenvia™, is a combination of two well-characterized compounds, the active ingredient dextromethorphan, and the enzyme inhibitor quinidine, which serves to increase the bioavailability of dextromethorphan. This first-in-class dual action glutamate inhibitor is believed to help regulate excitatory neurotransmission to diminish the unpredictable emotional episodes of pseudobulbar affect (PBA). AVANIR is developing AVP-923 for use in PBA (also known as involuntary emotional expression disorder (IEED) and emotional lability) and diabetic peripheral neuropathic pain.

For more information on PBA:

For more information on AVP-923 for Diabetic Peripheral Neuropathic (DPN) Pain: